Investment Thesis
Evommune is a pre-revenue pharmaceutical company burning cash at an unsustainable rate with -$76.4M operating cash flow against only $44.1M in remaining cash reserves. The company generates minimal revenue ($13M) while operating at massive losses (-$81.1M operating income, -$529.8% net margin), indicating either failed commercialization or continued R&D phase without near-term profitability. With current burn rate, cash runway appears limited to approximately 6-7 months without additional financing.
Strengths
- Strong balance sheet with $205.6M stockholders' equity and low leverage (0.00x debt/equity)
- Excellent liquidity position with 8.57x current ratio providing short-term financial flexibility
- Substantial asset base of $224.9M suggesting tangible R&D infrastructure and intellectual property
Risks
- Critical cash burn rate of -$76.4M annually with only $44.1M cash remaining creates severe liquidity crisis risk
- Massive negative margins (-623.6% operating, -529.8% net) indicate business model is fundamentally not generating profits at any scale
- Minimal revenue generation of $13M with zero YoY growth suggests failed commercialization, clinical delays, or non-operational status
- Free cash flow of -$76.7M indicates company is consuming capital faster than equity cushion can sustain
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue growth trajectory and regulatory approvals/clinical trial progress
- Quarterly operating cash flow trends and operating expense reduction
- Dilution from future financing rounds and equity offerings
Financial Metrics
Revenue
13.0M
Net Income
-68.9M
EPS (Diluted)
$-11.22
Free Cash Flow
-76.7M
Total Assets
224.9M
Cash
44.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-623.6%
Net Margin
-529.8%
ROE
-33.5%
ROA
-30.6%
FCF Margin
-589.8%
Balance Sheet & Liquidity
Current Ratio
8.57x
Quick Ratio
8.57x
Debt/Equity
0.00x
Debt/Assets
8.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T15:16:11.507071 |
Data as of: 2025-12-31 |
Powered by Claude AI